Strategic Partnerships Recent collaboration with Whitehawk Therapeutics signals openness to co-development and technology-sharing deals. Leverage this trend to pursue tiered partnerships with CROs, specialty biotech firms, and large pharma interested in ADC payload innovations or combination therapies.

Novel Payload Focus PH1 spliceosome modulator as a differentiated payload opens conversations with companies exploring next generation ADCs and RNA-targeted cancer therapies. Position Akari as a collaborator for payload licensing, joint exploration, or targeted ADC programs across tumor types.

Lead Candidate Momentum AKTX-101 targets Trop2 with potential synergy with checkpoint inhibitors and favorable survival signals in preclinical data. Target collaborations around combination regimens, biomarker-enabled trials, and expansion into Trop2-expressing cancers.

Additional Programs AKTX-102 and other undisclosed targets using PH1 indicate a broader platform. Pursue licensing or development deals for second ADCs targeting CEACAM5 and other solid tumors, expanding portfolio access for potential partners.

Visibility & Funding Active conference presence, advisor recruitment, and a public collaboration trajectory enhance credibility. Use this momentum to approach strategic investors, co-development agreements, and joint venture opportunities with mid- to large-cap biopharma seeking innovative oncology assets.